Navigation Links
Hologic Announces Second Quarter Fiscal 2011 Operating Results
Date:5/2/2011

s: (i) an $84.5 million net gain on the sale of intellectual property; (ii) a $29.9 million non-cash loss on the exchange of Convertible Notes in the first quarter; (iii) a $4.2 million credit to operating expenses attributable to the net adjustment to record contingent consideration at fair value relating to the Sentinelle and Interlace acquisitions; and (iv) $5.7 million of acquisition-related costs and charges. The Company's non-GAAP adjusted net income for the first six months of fiscal 2010 also primarily excludes a charge of $12.5 million related to a legal settlement.

Non-GAAP adjusted net income, non-GAAP adjusted earnings per diluted share (non-GAAP adjusted EPS), and adjusted EBITDA are non-GAAP financial measures. The Company's definitions of these non-GAAP financial measures, and the reconciliations of these measures to the Company's comparable GAAP financial measures for the periods presented, are set forth in the supplemental information attached to this press release. When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.

As of March 26, 2011, total backlog for all products was $283.4 million.

"We had a strong quarter, resulting in a solid first half of fiscal 2011," said Rob Cascella, President and Chief Executive Officer. "Once again, revenues and operating performance exceeded our guidance. We pioneered the next-generation of digital mammography with the recent FDA approval of our Dimensions 3D system, the first 3D mammography system to receive approval. We are very excited to be able to offer women this ground-breaking imaging technology and we continue to gain very nice traction in sales of both our 2D and 3D Dimensions systems. In addition, we reported a record quarter in our breast biopsy business. Lastly, we are thrilled to have closed on our acquisition of Interlace Medical, adding My
'/>"/>

SOURCE Hologic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Hologic to Release Second Quarter Fiscal 2011 Operating Results on Monday, May 2, 2011
2. Hologic, Hospira, Boston Scientific, Allergan to Participate in Leading Medical Device Manufacturing Symposium
3. High Rates of Pathological Complete Response in Patients with Advanced Esophageal Cancer in OPAXIO™ Phase II Study Reported in American Journal of Clinical Oncology
4. Hologic Targets Womens Health Professionals at ECR 2011
5. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
6. Hologic Announces First Quarter Fiscal 2011 Operating Results
7. Hologic Appoints Mark D. Myslinski as Senior Vice President and General Manager of Diagnostics
8. Hologic Acquires Interlace Medical
9. Hologic to Release First Quarter Fiscal 2011 Operating Results on Monday, January 31, 2011
10. Hologic to Participate in Three Investor Conferences
11. Hologic Encourages Health Professionals to Get the Facts About Womens Imaging at RSNA 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... Nov. 23, 2014  Aurobindo Pharma USA ... Capsules, USP 300 mg 100-count bottles to the consumer ... some empty capsules. Empty capsules could result ... consequences that could range from no effect, short term ... epilepticus (long period seizures) that could be life-threatening. Aurobindo ...
(Date:11/22/2014)... , Nov. 21, 2014   Long Beach dentist , ... often called the gold standard in tooth replacement because they ... stable, long-lasting way to restore and preserve smiles and improve ... replace a missing tooth or as a part of a ... look and feel of a smile. The loss ...
(Date:11/22/2014)... HILL, N.C. , Nov. 21, 2014 /PRNewswire/ ... healthcare system. Undoubtedly, the growing influence of patients ... spend for marketing interactions. Now, more than ever, ... retain patients for medical products is essential. ... firm, Best Practices, LLC, benchmarked companies spent about ...
Breaking Medicine Technology:Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... 18 Epiphany Biosciences announced results from its Phase ... shingles (herpes zoster) infection. The study,s primary endpoint ... in terms of time to complete crusting of the ... randomized into 3 arms: 1 gram of once-daily ...
... Nov. 18 Covance Inc. (NYSE: CVD ), ... it entered into a biomarker alliance and services agreement with ... biomarker testing to the pharmaceutical industry. , Subject to the ... exclusive third-party provider of multiplexed protein biomarker testing services, and ...
Cached Medicine Technology:Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. 2Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. 3Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 2Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 3Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 4
(Date:11/23/2014)... November 23, 2014 Syngenta lawsuits are ... behalf of farmers and agribusinesses that have allegedly incurred ... commercialize Agrisure Viptera and Agrisure Duracade, genetically modified ... approved for sale in China. According to a report ... virtually ban U.S. corn imports. Because China is the ...
(Date:11/23/2014)... Lake City, Utah (PRWEB) November 23, 2014 ... individual health insurance reimbursement for small businesses, announced ... new book, The End of Employer-Provided Health Insurance. ... health insurance is the greatest financial risk facing ... challenge facing U.S. employers, small and large, when ...
(Date:11/22/2014)... Cancer researchers in New York and Minnesota ... tunnels and the growth and spread of mesothelioma. ... the Surviving Mesothelioma website. , Doctors at Memorial ... have just released their study on tunneling nanotubes (TnTs), ... They found that mesothelioma cells contain many ...
(Date:11/22/2014)... A classic black prom dress will never go out of ... unveiled its new items of black prom gowns . ... big discount, up to 70% off. People throughout the world ... prom dresses, made with the best materials, can make wearers ... customers, the company provides these beautiful outfits in a huge ...
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding ... the business offers a wide range of special occasion ... allowing them to create multiple looks easily. , According ... collection of chic wedding dresses has been prepared for ... discounted rates now. Dylan Queen can always create what ...
Breaking Medicine News(10 mins):Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2
... SHENZHEN, China, Sept. 21 /PRNewswire-Asia/ -- ... or the "Company"), a leading,exporter of medical dressing and ... sponsored the "2009 China Medical Textile Industry,Forum -- Innovation ... China. , The organizer of ...
... , , LINCOLN, R.I., Sept. 21 ... Americans report problems with chronic pain; more than diabetes, heart disease, ... of chronic pain in the United States, including healthcare expenses, lost ... , "Despite the obvious impact on our society and ...
... , , BIRMINGHAM, Ala., ... today announced that it has been awarded a $77.2 million contract ... to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous ... , "We are very excited to continue working ...
... , PRINCETON, N.J., Sept. 21 ... Company), a late-stage biotechnology company, announced today that it has ... Institute of Allergy and Infectious Diseases (NIAID), a division of ... over a five-year period, the development of formulation and manufacturing ...
... , , INDIANAPOLIS, Sept. 21 ... in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who ... care as compared to placebo plus best supportive care. ... previous studies looking at the use of histology to tailor treatment ...
... , , , ... today announced U.S. Food & Drug Administration clearance to market ... is the first and only blood glucose monitor that plugs ... information that can help optimize diabetes management. The CONTOUR USB ...
Cached Medicine News:Health News:Winner Medical Solely Sponsored the 2009 China Medical Textile Industry Forum 2Health News:Winner Medical Solely Sponsored the 2009 China Medical Textile Industry Forum 3Health News:Measuring Pain from the Patient's Point of View 2Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 2Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 3Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 4Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 5Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 2Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 3Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 4Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 5Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 6Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 2Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 3Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 4Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 5Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 6Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 7Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 8Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 2Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 3Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 4Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 5
... Pediatric Sarmiento-style PTB tibial orthosis ... Lined with closed-cell foam at bony ... Selection of 3 modular footpiece/shoe insert ... patient. Stretch Velcro® design fits especially ...
... is a lightweight patient friendly brace utilizing the ... The Escort provides patients with a lightweight ... Superior comfort and improved patient compliance is ... Escort Hip brace is the result of ...
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
Modular hip abduction system designed to provide superior fit, adjustability and functionality for optimum patient stability, comfort and compliance...
Medicine Products: